Last update 25 Dec 2025

Alcon-Couvreur NV

Subsidiary Company|1962|Belgium|
www.alconlabs.com

Overview

Tags

Eye Diseases
Nervous System Diseases
Cardiovascular Diseases
Small molecule drug
Single-chain FV antibody fragment
Polymer

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug2
Polymer1
Single-chain FV antibody fragment1
Top 5 TargetCount
VEGF-A(Vascular endothelial growth factor A)1
CAs(Carbonic anhydrases)1
β1-adrenergic receptor(Beta-1 adrenergic receptor)1

Related

4
Drugs associated with Alcon-Couvreur NV
Brolucizumab-dbll
Target
VEGF-A
Mechanism
VEGF-A inhibitors
Active Org.
China Novartis Institutes for BioMedical Research Co., Ltd. [+11]
Originator Org.
Novartis Pharma AG
Active Indication
Proliferative retinopathy with diabetes mellitus [+7]
Inactive Indication
Macular Edema [+4]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date07 Oct 2019
Brinzolamide
Target
CAs
Mechanism
CAs inhibitors
Active Org.
Novartis Europharm Ltd. [+4]
Originator Org.
Alcon AGAlcon AG
Active Indication
Glaucoma [+2]
Inactive Indication
Exfoliation Syndrome
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date01 Apr 1998
Betaxolol Hydrochloride
Target
β1-adrenergic receptor
Mechanism
β1-adrenergic receptor antagonists
Active Org.
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp. [+4]
Originator Org.
Novartis Pharma AG
Active Indication
Hypertension [+5]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date30 Aug 1985
1
Clinical Trials associated with Alcon-Couvreur NV
CTR20150111
/ CompletedPhase 3
布林佐胺10 mg/mL/溴莫尼定2 mg/mL混悬滴眼液与布林佐胺10 mg/mL混悬滴眼液 + 溴莫尼定2 mg/mL滴眼液对开角型青光眼/高眼压症疗效和安全性的比较
[Translation] Comparison of the efficacy and safety of brinzolamide 10 mg/mL/brimonidine 2 mg/mL suspension eye drops versus brinzolamide 10 mg/mL suspension eye drops + brimonidine 2 mg/mL eye drops for open-angle glaucoma/ocular hypertension
100 Clinical Results associated with Alcon-Couvreur NV
Login to view more data
0 Patents (Medical) associated with Alcon-Couvreur NV
Login to view more data
100 Deals associated with Alcon-Couvreur NV
Login to view more data
100 Translational Medicine associated with Alcon-Couvreur NV
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 Jan 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
NDA/BLA
1
3
Approved
Other
2
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free